Bottom line
CRCA vs CRCG: the short answer
CRCA (ProShares Ultra CRCL) and CRCG (Leverage Shares 2X Long CRCL Daily ETF) are both etfs.
CRCG is cheaper at 0.78% vs 0.95% — a difference of $17 a year per $10,000 invested.
Updated Nov 19, 2026
CRCA vs CRCG side by side
| CRCA | CRCG | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | ProShares | Themes |
| Category | Other | Leveraged & Inverse |
| Expense ratio | 0.95% | 0.78% |
| Annual cost per $10k | $95 | $78 |
| 10-yr cost on $10k (prospectus) | $1,231 | $966 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | — | — |
| 5-yr return (annualized) | — | — |
| 10-yr return (annualized) | — | — |
| Best quarter | — | — |
| Worst quarter | — | — |
| Net assets (fund) | $227.5M | $83.8M |
| Number of holdings | 11 | 6 |
| Portfolio turnover | % | % |
| Returns as of | — | — |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
7 of CRCA's top 11 holdings also appear in CRCG's top 6.
| Holding | CRCA | CRCG |
|---|---|---|
| N/a | 4.32% | -1.53% |
| N/a | 0.21% | -1.53% |
| N/a | -2.27% | -1.53% |
| N/a | -2.52% | -1.53% |
| N/a | -2.98% | -1.53% |
| N/a | -3.09% | -1.53% |
| N/a | -4.42% | -1.53% |
Source: SEC Form N-PORT
CRCA top 10
- Repurchase Agreement — 6.18%
- N/a — 4.32%
- Repurchase Agreement — 3.89%
- Repurchase Agreement — 2.92%
- Repurchase Agreement — 2.14%
- N/a — 0.21%
- N/a — -2.27%
- N/a — -2.52%
- N/a — -2.98%
- N/a — -3.09%
CRCG top 10
- First American Treasury Obliga — 5.12%
- N/a — 1.05%
- N/a — -0.28%
- N/a — -0.72%
- N/a — -1.15%
- N/a — -1.53%
FAQ
What is the difference between CRCA and CRCG?
CRCA (ProShares Ultra CRCL) and CRCG (Leverage Shares 2X Long CRCL Daily ETF) are both etfs. CRCG is cheaper at 0.78% vs 0.95% — a difference of $17 a year per $10,000 invested.
Which is cheaper, CRCA or CRCG?
CRCG has the lower expense ratio (0.78%).
Should I own both CRCA and CRCG?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.